You can buy or sell Verona Pharma and other stocks, options, ETFs, and crypto commission-free!
Verona Pharma Plc operates as a clinical-stage biopharmaceutical company focused on developing and commercializing therapeutics for the treatment of respiratory diseases. It's product include, RPL554, is a dual inhibitor of the enzymes phosphodiesterase 3 and 4 that acts as both a bronchodilator and an anti-inflammatory agent in a single compound. Read More The firm develops RPL554 for the treatment of chronic obstructive pulmonary disease (COPD), cystic fibrosis, and potentially asthma. The company was founded by Michael J. A. Walker and Clive P. Page on February 24, 2005 and is headquartered in London, United Kingdom.
London, Greater London
52 Week High
52 Week Low
Expected Aug 7, Pre-Market